Fosaprepitant
Active ingredient
Sold as Ivemend · EMEND IV
- Drug class
- -
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 8
Overview
Fosaprepitant is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 1, 2026 |
| CA Canada | Health Canada | 3 | September 4, 2025 |
| US United States | FDA | 1 | April 1, 2026 |
| EU European Union | EMA | 1 | November 5, 2025 |
GBUnited Kingdom· MHRA
3 products
Uses
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. 2).
How to take
CACanada· Health Canada
3 products
Uses
AND CLINICAL USE..................................................................................... 3 CONTRAINDICATIONS ....................................................................................................... 3 WARNINGS AND PRECAUTIONS.......................................................................................
4 ADVERSE REACTIONS ...................................................................................................... 5 DRUG INTERACTIONS .......................................................................................................
31 FOSAPREPITANT Product Monograph Page 3 of 33 Pr FOSAPREPITANT Fosaprepitant for Injection PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength Non-medicinal Ingredients Intravenous Lyophilized powder / 150 mg per vial Edetate disodium, lactose anhydrous, polysorbate 80 and sodium hydroxide and/or hydrochloric acid (for pH adjustment).
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant has not been studied for the treatment of established nausea and vomiting. Fosaprepitant for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use ( 1 ) Fosaprepitant for injection has not been studied for treatment of established nausea and vomiting.
EUEuropean Union· EMA
1 product
Uses
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. 2).
How to take
Drug interactions
Known interactions involving Fosaprepitant. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 325. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL154130181 · revised April 17, 2026
- [2]Health Canada (DPD) · 02436264 · revised March 22, 2025
- [3]FDA DailyMed · 19919480-960b-47… · revised April 1, 2026 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000743 · revised November 5, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.